Literature DB >> 21877256

Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration.

Eric S Richardson1, Christopher Rolfes, Oh Sang Woo, William F Elmquist, David G Benditt, Paul A Iaizzo.   

Abstract

Anti-arrhythmic drugs have narrow therapeutic ranges and typically can engender harmful side effects. The intrapericardial (IP) delivery of anti-arrhythmic agents proposes to achieve higher myocardial levels while minimizing plasma concentrations, thus diminishing systemic side effects. Furthermore, IP delivery enables concentrations at the target site to be more precisely controlled. Our study objective was to compare the relative cardiac effects of intrapericardial administration of metoprolol to standard intravenous (IV) delivery in a swine surgical model. In order to answer the question of how IP metoprolol affects sinus tachycardia, atrial electrophysiology, and pharmacokinetics compared with IV delivery, a medial sternotomy was performed on 21 swine that were divided into three groups: (1) After inducing sinus tachycardia, metoprolol boluses were delivered IP (n = 4) or IV (n = 4); (2) metoprolol was administered either IP (n = 3) or IV (n = 3) with saline controls (n = 3), and electrophysiologic data were collected; (3) metoprolol levels were tracked both in the blood (IV, n = 2) and pericardial (IP, n = 2) fluid. After either IP or IV delivery of metoprolol, heart rates were lowered significantly to 70% and 73% of control rate, respectively. The therapeutic effect of IV-administered metoprolol was considerably reduced after 1 h but was sustained longer in the IP group. Additionally, ventricular contractility and mean arterial pressure parameters were significantly lower in IV-treated animals but were nearly unaffected in IP-treated animals. With IP administration, the elimination half-life of metoprolol in pericardial fluid was 14.4 min with negligible accumulations in the plasma, whereas with IV delivery, the elimination half-life in plasma was 11.1 min with negligible amounts found in the pericardial fluid. The targeted intrapericardial delivery of metoprolol effectively lowers heart rates for sustained periods of time, with minimal effect on either ventricular contractility or mean arterial pressure. We did not observe dramatic changes in induced atrial fibrillation times or refractory periods using this model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21877256     DOI: 10.1007/s12265-011-9315-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  11 in total

1.  Distribution of amiodarone in heart tissues following intrapericardial administration.

Authors:  J T Darsinos; J N Karli; E C Samouilidou; B Krumbholz; A C Pistevos; G M Levis
Journal:  Int J Clin Pharmacol Ther       Date:  1999-06       Impact factor: 1.366

2.  Intrapericardial delivery enhances cardiac effects of sotalol and atenolol.

Authors:  Thomas J van Brakel; J J Rob Hermans; Ben J Janssen; Helma van Essen; Nicole Botterhuis; Jos F M Smits; Jos G Maessen
Journal:  J Cardiovasc Pharmacol       Date:  2004-07       Impact factor: 3.105

3.  Enantioselective analysis of metoprolol in plasma using high-performance liquid chromatographic direct and indirect separations: applications in pharmacokinetics.

Authors:  V L Lanchote; P S Bonato; P M Cerqueira; V A Pereira; E J Cesarino
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-01-28

4.  Pericardial prostaglandin biosynthesis prevents the increased incidence of reperfusion-induced ventricular fibrillation produced by efferent sympathetic stimulation in dogs.

Authors:  T Miyazaki; D P Zipes
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

5.  Intrapericardial drug delivery: pharmacologic properties and long-term safety in swine.

Authors:  Theofilos M Kolettis; Nikolaos Kazakos; Christos S Katsouras; Dimitra Niokou; Lamprini Pappa; Vassilios Koulouras; Panagiotis Stefanou; Constantinos Seferiadis; Vassiliki Malamou-Mitsi; Lampros K Michalis; Marios Marselos; Dimitrios A Sideris
Journal:  Int J Cardiol       Date:  2005-03-30       Impact factor: 4.164

6.  Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: nitric oxide modulates sympathetic effects on ventricular electrophysiological properties.

Authors:  L Fei; A D Baron; D P Henry; D P Zipes
Journal:  Circulation       Date:  1997-12-02       Impact factor: 29.690

7.  Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery.

Authors:  Michael R Ujhelyi; Kelly Z Hadsall; David E Euler; Rahul Mehra
Journal:  J Cardiovasc Electrophysiol       Date:  2002-06

8.  Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation.

Authors:  G M Ayers; T H Rho; J Ben-David; H R Besch; D P Zipes
Journal:  J Cardiovasc Electrophysiol       Date:  1996-08

9.  Potent antifibrillatory effects of intrapericardial nitroglycerin in the ischemic porcine heart.

Authors:  Kapil Kumar; Khanh Nguyen; Sergio Waxman; Bruce D Nearing; Gregory A Wellenius; Susan X Zhao; Richard L Verrier
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

10.  Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs.

Authors:  András Vereckei; J Cristopher Gorski; Michael Ujhelyi; Rahul Mehra; Douglas P Zipes
Journal:  Cardiovasc Drugs Ther       Date:  2004-07       Impact factor: 3.727

View more
  3 in total

Review 1.  Interventional Pericardiology.

Authors:  Mandeep Bhargava; Oussama M Wazni; Walid I Saliba
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

2.  Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine.

Authors:  Tinen L Iles; Brian Howard; Stephen Howard; Stephen Quallich; Christopher Rolfes; Eric Richardson; Hanna R Iaizzo; Paul A Iaizzo
Journal:  J Vis Exp       Date:  2016-07-07       Impact factor: 1.355

3.  The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction.

Authors:  Verónica Crisóstomo; Claudia Baéz-Diaz; Virginia Blanco-Blázquez; Verónica Álvarez; Esther López-Nieto; Juan Maestre; Antoni Bayes-Genis; Carolina Gálvez-Montón; Javier G Casado; Francisco M Sánchez-Margallo
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.